Genetic modification of T cells for cancer therapy

Journal of Biological Regulators and Homeostatic Agents

Volumn 18, Issue 1, 2004, Pages 62-71

  Imai, C ^a   Campana, Dario ^a  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

CD137; CD28; Lentiviral vectors; Retroviral vectors; T cell receptor

Indexed keywords

6 THIOXANTHINE; ANTINEOPLASTIC AGENT; B7 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CD137 ANTIGEN; CD19 ANTIGEN; CD20 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CD33 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CHIMERIC ANTIBODY; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUCYTOSINE; FLUDARABINE; FOLATE BINDING PROTEIN; GANCICLOVIR; GANGLIOSIDE GD3; HIGH MOLECULAR WEIGHT KININOGEN; INTERLEUKIN 2; INTERLEUKIN 7; LENTIVIRUS VECTOR; MELANOMA ANTIGEN 1; METHOTREXATE; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; THYMIDINE KINASE; UNINDEXED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER RESEARCH; CELL SPECIFICITY; CELLULAR IMMUNITY; CHIMERA; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DNA MODIFICATION; DRUG RECEPTOR BINDING; FEASIBILITY STUDY; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; PROTEIN DOMAIN; REVIEW; T LYMPHOCYTE ACTIVATION; VIRAL GENE DELIVERY SYSTEM;

ANIMALIA; MURINAE;

EID: 4444291026     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (109)

1. Billingham RE, Brent L, Medawar PB. Quantitative studies on tissue transplantation immunity II. The origin, strength and duration of actively and adoptively acquired immunity. Proceedings Royal Soc 1954; 143: 58-80.
2. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998; 92: 1549-55.
3. Wagner HJ, Bollard CM, Vigouroux S, et al. A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells. Cancer Gene Ther 2004; 11: 81-91.
4. Comoli P, De Palma R, Siena S, et al. Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma. Ann Oncol 2004; 15: 113-7.
5. Yotnda P, Firat H, Garcia-Pons F, et al. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest 1998; 101: 2290-6.
6. Chen W, Qin H, Reese VA, Cheever MA. CTLs specific for bcr-abl joining region segment peptides fail to lyse leukemia cells expressing p210 bcr-abl protein. J Immunother 1998; 21: 257-68.
7. Clay TM, Custer MC, Sachs J, Hwu P, Rosenberg SA, Nishimura MI. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol 1999; 163: 507-13.
8. Stanislawski T, Voss RH, Lotz C, et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol 2001; 2: 962-70.
9. Orentas RJ, Roskopf SJ, Nolan GP, Nishimura MI. Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide. Clin Immunol 2001; 98: 220-8.
10. Willemsen RA, Weijtens ME, Ronteltap C, et al. Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR. Gene Ther 2000; 7: 1369-77.
11. Kuwana Y, Asakura Y, Utsunomiya N, et al. Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions. Biochem Biophys Res Commun 1987; 149: 960-8.
12. Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA 1989; 86:10024-8.
13. Becker ML, Near R, Mudgett-Hunter M, et al. Expression of a hybrid immunoglobulin-T cell receptor protein transgenic mice. Cell 1989; 58: 911-21.
14. Goverman J, Gomez SM, Segesman KD, Hunkapiller T, Laug WE, Hood L. Chimeric immunoglobulin-T cell receptor proteins form functional receptors: Implications for T cell receptor complex formation and activation. Cell 1990; 60: 929-39.
15. Moritz D, Groner B. A spacer region between the single chain antibody- and the CD3 zeta-chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity. Gene Ther 1995; 2: 539-46.
16. Clackson T, Hoogenboom HR, Griffiths AD, Winter G. Making antibody fragments using phage display libraries. Nature 1991; 352: 624-8.
17. Cai X, Garen A. Anti-melanoma antibodies from melanoma patients immunized with genetically modified autologous tumor cells: Selection of specific antibodies from single-chain Fv fusion phage libraries. Proc Natl Acad Sci USA 1995; 92: 6537-41.
18. Willemsen RA, Debets R, Hart E, Hoogenboom HR, Bolhuis RL, Cherries P. A phage display selected fab fragment with MHC class I-restricted specificity for MAGE-A1 allows for retargeting of primary human T lymphocytes. Gene Ther 2001; 8: 1601-8.
19. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 1993; 90: 720-4.
20. Stancovski I, Schindler DG, Waks T, Yarden Y, Sela M, Eshhar Z. Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors. J Immunol 1993; 151: 6577-82.
21. Sadelain M, Riviere I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 2003; 3:35-45.
22. Geiger TL, Leitenberg D, Flavell RA. The TCR zetachain immunoreceptor tyrosine-based activation motifs are sufficient for the activation and differentiation of primary T lymphocytes. J Immunol 1999; 162:5 931-9.
23. Haynes NM, Snook MB, Trapani JA, et al. Redirecting mouse CTL against colon carcinoma: Superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma. J Immunol 2001; 166:182-7.
24. Geiger TL, Nguyen P, Leitenberg D, Flavell RA. Integrated src kinase and costimulatory activity enhances signal transduction through single-chain chimeric receptors in T lymphocytes. Blood 2001; 98: 2364-71.
25. Liebowitz DN, Lee KP, June CH. Costimulatory approaches to adoptive immunotherapy. Curr Opin Oncol 1998; 10: 533-41.
26. Allison JP, Lanier LL. Structure, function, and serology of the T-cell antigen receptor complex. Annu Rev Immunol 1987; 5: 503-40.
27. Salomon B, Bluestone JA. Complexities of CD28/137: CTLA-4 costimulatory pathways in autoimmonity and transplantation. Annu Rev Immunol 2001; 19: 225-52.
28. Gong MC, Latouche JB, Krause A, Heston WD, Bander NH, Sadelain M. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia 1999; 1: 123-7.
29. Maher J, Brenjens RJ, Gunset G, Riviere I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat Biotechnol 2002; 20: 70-5.
30. Brentjens RJ, Latouche JB, Santos E, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 2003; 9: 279-86.
31. Eshhar Z, Waks T, Bendavid A, Schindler DG. Functional expression of chimeric receptor genes in human T cells. J Immunol Methods 2001; 248: 67-76.
32. Hombach A, Wieczarkowiecz A, Marquardt, et al. Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule. J Immunol 2001; 167: 6123-31.
33. Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, Jane SM, et al. Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood 2002; 100: 3155-63.
34. Takahashi C, Mittler RS, Vella AT. Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. J Immunol 1999; 162: 5037-40.
35. Sica G, Chen L. Modulation of the immune response through 4-1BB. In: Habib N, ed. Cancer gene therapy: Past achievements and future challenges. New York: Kluwer Academic/Plenum Publishers, 2000: pp 355-62.
36. Kim YJ, Kim SH, Mantel P, Kwon BS. Human 4-1BB regulates CD28 co-stimulation to promote Th1 cell responses. Eur J Immunol 1998; 28: 881-90.
37. Hurtado JC, Kim YJ, Kwon BS. Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death. J Immunol 1997; 158: 2600-9.
38. DeBenedette MA, Shahinian A, Mak TW, Watts TH. Costimulation of CD28- T lymphocytes by 4-1BB ligand. J Immunol 1997; 158: 551-9.
39. Bukczynski J, Wen T, Wafts TH. Costimulation of human CD28-T cells by 4-1BB ligand. Eur J Immunol 2003; 33: 446-54.
40. Shuford WW, Klussman K, Tritchler DD, et al. 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J Exp Med 1997; 186: 47-55.
41. Martinet O, Divino CM, Zang Y, et al. T cell activation with systemic agonistic antibody versus local 4-1BB ligand gene delivery combined with interleukin-12 eradicate liver metastases of breast cancer. Gene Ther 2002; 9: 786-92.
42. May KF Jr, Chen L, Zheng P, Liu Y. Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells. Cancer Res 2002; 62: 3459-65.
43. Melero I, Shuford WW, Newby SA, et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997; 3: 682-5.
44. Melero I, Bach N, Hellstrom KE, Aruffo A, Mittler RS, Chen L. Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: Synergy with the CD28 co-stimulatory pathway. Eur J Immunol 1998; 28: 1116-21.
45. Ye Z, Hellstrom I, Hayden-Ledbetter M, Dahlin A, Ledbetter JA, Hellstrom KE. Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB. Nat Med 2002; 8: 343-8.
46. Mogi S, Sakurai J, Kohsaka T, et al. Tumour rejection by gene transfer of 4-1BB ligand into a CD80(+) murine squamous cell carcinoma and the requirements of costimulatory molecules on tumour and host cells. Immunology 2000; 101: 541-7.
47. Yoshida H, Katayose Y, Unno M, et al. A novel adenovirus expressing human 4-1BB ligand enhances antitumor immunity. Cancer Immunol Immunother 2003; 52: 97-106.
48. Li Y, Hellstrom KE, Newby SA, Chen L. Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors. J Exp Med 1996; 183: 639-44.
49. Imai C, Mihara K, Andreansky M, Nicholson IC, Pui CH, Campana D. Chimeric receptors with 4-1BB signaling, capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 2004; 18: 676-84.
50. Hanazono Y, Brown KE, Dunbar CE. Primary T lymphocytes as targets for gene therapy. J Hematother Stem Cell Res 2000; 9: 611-20.
51. Kootstra NA, Verma IM. Gene therapy with viral vectors. Annu Rev Pharmacol Toxicol 2003; 43: 413-39.
52. Benihoud K, Yeh P, Perricaudet M. Adenovirus vectors for gene delivery. Curr Opin Biotechnol 1999; 10: 440-7.
53. Bahnson AB, Dunigan JT, Baysal BE, et al. Centrifugal enhancement of retroviral mediated gene transfer. J Virol Methods 1995; 54: 131-43.
54. Hanenberg H, Xiao XL, Dilloo D, Hashino K, Kato I, Williams DA. Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nat Med 1996; 2: 876-82.
55. Barry SC, Seppen J, Ramesh N, et al. Lentiviral and murine retroviral transduction of T cells for expression of human CD40 ligand. Hum Gene Ther 2000; 11: 323-32.
56. Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996; 2: 551-5.
57. Roskrow MA, Suzuki N, Gan Y, et al. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood 1998; 91: 2925-34.
58. Mitsuyasu RT, Anton PA, Deeks SG, et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood 2000; 96: 785-93.
59. Rossig C, Bollard CM, Nuchtern JG, Rooney CM, Brenner MK. Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: Potential for improved immunotherapy. Blood 2002; 99: 2009-16.
60. Tiberghien P, Ferrand C, Lioure B, et al. Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood 2001; 97: 63-72.
61. Marktel S, Magnani Z, Ciceri F, et al. Immunologic potential of donor lymphocytes expressing a suicide gone for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation. Blood 2003; 101: 1290-8.
62. Spencer DM. Developments in suicide genes for preclinical and clinical applications. Curr Opin Mol Ther 2000; 2: 433-40.
63. Thomis DC, Marktel S, Bonini C, et al. A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood 2001; 97: 1249-57.
64. MacCorkle RA, Freeman KW, Spencer DM. Synthetic activation of caspases: Artificial death switches. Proc Natl Acad Sci USA 1998; 95: 3655-60.
65. Chang DW, Yang X. Activation of procaspases by FK506 binding protein-mediated oligomerization. Sci STKE 2003; 2003: PL1.
66. Introna M, Barbui AM, Bambacionio F, et al. Genetic modification of human T cells with CD20: A strategy to purify and lyse transduced cells with anti-CD20 antibodies. Hum Gene Ther 2000; 11: 611-20.
67. Pui CH, Campana D, Evans WE. Childhood acute lymphoblastic leukemia - Current status and future perspectives. Lancet Oncology 2001; 2: 597-607.
68. Verma A, Stock W. Management of adult acute lymphoblastic leukemia: Moving toward a risk-adapted approach. Curr Opin Oncol 2001; 13: 14-20.
69. Champlin R. T-cell depletion to prevent graft-versus-host disease after bone marrow transplantation. Hematol Oncol Clin North Am 1990; 4: 687-98.
70. Porter DL, Antin JH. The graft-versus-leukemia effects of allogeneic cell therapy. Annu Rev Med 1999; 50: 369-86.
71. Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature 2001; 411: 385-9.
72. Porter DL, Roth MS, McGarigle C, Ferrara JL, Antin JH. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 1994; 330:100-6.
73. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86: 2041-50.
74. Slavin S, Naparstek E, Nagler A, et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996; 87: 2195-204.
75. Collins RH, Jr., Shpilberg O, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433-44.
76. Verdonck LF, Petersen EJ, Lokhorst HM, et al. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: Impact of infused and residual donor T cells. Bone Marrow Transplant 1998; 22: 1057-63.
77. Collins RH Jr, Goldstein S, Giralt S, et al. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant 2000; 26: 511-6.
78. Campana D, Behm FG. Immunophenotyping of leukemia. J Immunol Methods 2000; 243: 59-75.
79. Nadler LM, Anderson KC, Marti G, et al. B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. J Immunol 1983; 131: 244-50.
80. Cooper LJ, Topp MS, Serrano LM,. et al. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood 2003; 101: 1637-44.
81. Cardoso AA, Schultze JL, Boussiotis VA, et al. Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. Blood 1996; 88:41-8.
82. Manabe A, Coustan-Smith E, Behm FG, Raimondi SC, Campana D. Bone marrow-derived stromal cells prevent apoptotic cell death in B-lineage acute lymphoblastic leukemia. Blood 1992; 79: 2370-7.
83. Nishigaki H, Ito C, Manabe A, et al. Prevalence and growth characteristics of malignant stem cells in B-lineage acute lymphoblastic leukemia. Blood 1997; 89: 3735-44.
84. Mihara K, Imai C, Coustan-Smith E, et al. Development and functional characterization of human bone marrow mesenchymal cells immortalized by enforced expression of telomerase. Br J Haematol 2003; 120: 846-9.
85. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333: 1038-44.
86. Rooney CM, Smith CA, Ng CY, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995; 345: 9-13.
87. Geiger TL, Jyothi MD. Development and application of receptor-modified T lymphocytes for adoptive immunotherapy. Transfus Med Rev 2001; 15: 21-34.
88. Schumacher TN. T-cell-receptor gene therapy. Nat Rev Immunol 2002; 2: 512-9.
89. Maus MV, Thomas AK, Leonard DG, et al. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol 2002; 20: 143-8.
90. Lamers CH, Willemsen RA, Luider BA, Debets R, Bolhuis RL. Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer. Cancer Gene Ther 2002; 9: 613-23.
91. Baum C, Dullmann J, Li Z, et al. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood 2003; 101: 2099-114.
92. Hacein-Bey-Abina S, von Kalie C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415-9.
93. Campana D. Determination of minimal residual disease in leukemia patients. Br J Haematol 2003; 121: 823-38.
94. Moritz D, Wels W, Mattern J, Groner B. Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc Natl Acad Sci USA 1994; 91: 4318-22.
95. Altenschmidt U, Kahl R, Moritz D, et al. Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes. Clin Cancer Res 1996; 2: 1001-8.
96. Gritzapis AD, Mamalaki A, Kretsovali A, et al. Redirecting mouse T hybridoma against human breast and ovarian carcinomas: In vivo activity against HER2/neu expressing cancer cells. Br J Cancer 2003; 88: 1292-300.
97. Parker LL, Do MT, Westwood JA, et al. Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer. Hum Gene Ther 2000; 11: 2377-87.
98. Kershaw MH, Westwood A Hwu P. Dual-specific T cells combine proliferation and antitumor activity. Nat Biotechnol 2002; 20: 1221-7.
99. Hombach A, Heuser C, Sircar R, et al. T cell targeting of TAG72+ tumor cells by a chimeric receptor with antibody-like specificity for a carbohydrate epitope. Gastroenterology 1997; 113: 1163-70.
100. McGuinness RP, Ge Y, Patel SD, et al. Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor. Hum Gene Ther 1999; 10: 165-73.
101. Daly T, Royal RE, Kershaw MH, et al. Recognition of human colon cancer by T cells transduced with a chimeric receptor gene. Cancer Gene Ther 2000; 7: 284-91.
102. Yun CO, Nolan KF, Beecham EJ, Reisfeld RA, Junghans RP. Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors. Neoplasia 2000; 2: 449-59.
103. Abken H, Hombach A, Heuser C, Reinhold U. A novel strategy in the elimination of disseminated melanoma cells: Chimeric receptors endow T cells with tumor specificity. Recent Results Cancer Res 2001; 158: 249-64.
104. Krause A, Guo HF, Latouche JB, Tan C, Cheung NK, Sadelain M. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J Exp Med 1998; 188: 619-26.
105. Rossig C, Bollard CM, Nuchtern JG, Merchant DA, Brenner MK. Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. Int J Cancer 2001; 94: 228-36.
106. Ren-Heidenreich L, Hayman GT, Trevor KT. Specific tageting of EGP-2+ tumor cells by primary lymphocytes modified with chimeric T cell receptors. Hum Gene Ther 2000; 1: 9-19.
107. Cheung NK, Guo HF, Modak S, Cheung IY. Anti-idiotypic antibody facilitates scFv chimeric immune receptor gene transduction and clonal expansion of human lymphocytes for tumor therapy. Hybrid Hybridomics; 2003; 22: 209-18.
108. Finney HM, Lawson AD, Bebbington CR, Weir AN. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol 1998; 161: 2791-7.
109. Jensen M, Tan G, Forman S, Wu AM, Raubitschek A. CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: Implications for cellular immunotherapy of CD20+ malignancy. Biol Blood Marrow Transplant 1998; 4: 75-83.